ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Lu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jian, Hong; Chen, Chengshui; Jin, Xiangming; Tian, Panwen; Wang, Kai; Jiang, Guanming; Chen, Gongyan; Chen, Qun; Zhao, Hui; Ding, Cuimin; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Liu, Zhe; Fang, Jian; Yang, Junquan; Zhuang, Wu; Liu, Yunpeng; Zhang, Jian; Pan, Yueyin; Chen, Jun; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, Yan安徽医科大学; 北京大学; 华中科技大学; 吉林大学; 南京大学; 青岛大学; 上海交通大学; 哈尔滨医科大学; 河北医科大学; 四川大学; 浙江大学; 郑州大学; 中国人民解放军第四军医大学; 中国医科大学; 重庆大学; 中国科学院研究生院; 1; 东莞市人民医院
Journal of Thoracic Oncology2022-10DOI: 10.1016/j.jtho.2022.06.002
7被引7阅读
引用收藏
分享

摘要

Introduction: Befotertinib (D-0316) is a novel, third -generation EGFR tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first-or second -generation EGFR TKI therapy.Methods: This was a single-arm, open-label, phase 2 study at 49 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC harboring EGFR T790M mutations with disease progression after prior first-or second-generation EGFR TKI therapy received oral befo-tertinib of 50 mg (cohort A) or 75 to 100 mg (cohort B) once daily. The primary end point was objective response rate (ORR) assessed by an independent review committee in intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT03861156.Results: A total of 176 patients and 290 patients were included in cohorts A (50 mg) and B (75-100 mg), respectively. At data cutoff (August 15, 2021), independent review committee-assessed ORR was 67.6% (95% confi-dence interval [CI]: 61.9%-72.9%) in cohort B. The investigator-assessed ORR was 54.0% (95% CI: 46.3%- 61.5%) in cohort A and 65.9% (95% CI: 60.1%-71.3%) in cohort B. The median investigator-assessed progression-free survival was 11.0 (95% CI: 9.6-12.5) months in cohort A and 12.5 (95% CI: 11.1-13.8) months in cohort B. The median independent review committee-assessed progres-sion-free survival in cohort B was 16.6 (95% CI: 15.0-not evaluable [NE]) months. The intracranial ORR was 26.7% (95% CI: 7.8%-55.1%) in cohort A by investigator assess-ment, while 57.1% (95% CI: 34.0%-78.2%) and 55.9% (95% CI: 37.9%-72.8%) in cohort B by investigator and independent review committee assessment, respectively. The median investigator-assessed intracranial progression-free survival was 16.5 (95% CI: 8.6-NE) months in cohort A, while the median intracranial progression-free survival was not evaluable in cohort B due to immature data regardless of investigator or independent review committee assessment. and NE (95% CI: 13.8-NE) in cohort B. The overall survival was immature. Grade 3 or higher treatment-related adverse events and treatment-related serious adverse events occurred in 20.5% and 11.4% of patients in cohort A and in 29.3% and 10.0% of patients in cohort B, respectively. Conclusions: Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation with resistance to first-or second-generation EGFR TKIs. A phase 3 randomized trial is underway (NCT04206072).(c) 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

学科与关键词

关键词
BefotertinibEGFRNSCLCT790MEfficacy
相关
加载中…
  • Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
    Lu, Shun*; Zhou, Jianying*; Jian, Hong; Wu, Lin; Cheng, Ying; Fan, Yun; Fang, Jian; Chen, Gongyan; Zhang, Zhihong; Lv, Dongqing; Jiang, Liyan; Wu, Rong; Jin, Xiangming; Zhang, Xiaodong; Zhang, Junhong; Xie, Conghua; Sun, Gengyun; Huang, Dongning; Cui, Jiuwei; Guo, Renhua; Han, Zhigang; Chen, Zhendong; Liang, Jin; Zhuang, Wu; Hu, Xingsheng; Zang, Aimin; Zhang, Yi; Cang, Shundong; Lan, Yuanbo; Chen, Xi; Liu, Laiyu; Li, Xingya; Chen, Jun; Ma, Rui; Guo, Yanzhen; Sun, PingLancet Respiratory Medicine, 2023, 11(10): 905-915.被引 6
  • A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
    Lu, S.; Zhang, Y.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Guo, R.; Sun, G.; Wang, B.; Jiang, L.; Liu, Z.; Fang, J.; Yang, J.; Zhuang, W.; Liu, Y.; Zhang, J.; Pan, Y.; Chen, J.; Yu, Q.; Zhao, M.; Cui, J.; Li, D.; Yi, T.; Yu, Z.; Yang, Y.; Zhang, Y.; Zhi, X.; Huang, Y.; Wu, R.; Chen, L.; Zang, A.; Cao, L.; Li, Q.; Li, X.; Song, Y.; Wang, D.; Zhang, S.
  • Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Lu, S.; Zhang, Y.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Ding, L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Oncology
发表日期
2022-10
卷期
第 17 卷, 第 10 期
页码
1192-1204
DOI
10.1016/j.jtho.2022.06.002
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Betta Pharmaceuticals; National Key R&D Program of China [2016YFC1303300]; National Natural Science Foundation of China [82030045]; Shanghai Municipal Science & Technology Commission Research Project [17431906103, 19411950500]

作者

  • L

    Lu, Shun (第一作者)

  • Z

    Zhang, Yiping

查看全部 55 位作者收起作者
  • Z

    Zhang, Guojun

  • Z

    Zhou, Jianying

  • C

    Cang, Shundong

  • C

    Cheng, Ying

  • W

    Wu, Gang

  • C

    Cao, Peiguo

  • L

    Lv, Dongqing

  • J

    Jian, Hong

  • C

    Chen, Chengshui

  • J

    Jin, Xiangming

  • T

    Tian, Panwen

  • W

    Wang, Kai

  • J

    Jiang, Guanming

  • C

    Chen, Gongyan

  • C

    Chen, Qun

  • Z

    Zhao, Hui

  • D

    Ding, Cuimin

  • G

    Guo, Renhua

  • S

    Sun, Guoping

  • W

    Wang, Bin

  • J

    Jiang, Liyan

  • L

    Liu, Zhe

  • F

    Fang, Jian

  • Y

    Yang, Junquan

  • Z

    Zhuang, Wu

  • L

    Liu, Yunpeng

  • Z

    Zhang, Jian

  • P

    Pan, Yueyin

  • C

    Chen, Jun

  • Y

    Yu, Qitao

  • Z

    Zhao, Min

  • C

    Cui, Jiuwei

  • L

    Li, Dianming

  • Y

    Yi, Tienan

  • Y

    Yu, Zhuang

  • Y

    Yang, Yan

  • Z

    Zhang, Yan

  • Z

    Zhi, Xiuyi

  • H

    Huang, Yunchao

  • W

    Wu, Rong

  • C

    Chen, Liangan

  • Z

    Zang, Aimin

  • C

    Cao, Lejie

  • L

    Li, Qingshan

  • L

    Li, Xiaoling

  • S

    Song, Yong

  • W

    Wang, Donglin

  • Z

    Zhang, Shucai

  • D

    Ding, Lieming

  • Z

    Zhang, Ling

  • Y

    Yuan, Xiaobin

  • Y

    Yao, Lin

  • S

    Shen, Zhilin

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417